Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 46th Annual Meeting of the European Association for the Study of Diabetes
Importance of Comprehensive Control in Type 2 Diabetes
Stockholm, Sweden / September 20-24, 2010
Stockholm - Management of type 2 diabetes has evolved into multifaceted clinical strategies. Extensive research and clinical experience have shown that focusing on a single target—such as fasting blood glucose—overlooks other parameters...
PRIORITY PRESS - 20th Annual Congress of the European Respiratory Society
Improving the Management of Pulmonary Arterial Hypertension
Barcelona, Spain / September 18-22, 2010
Barcelona - Although the outlook for patients with pulmonary arterial hypertension (PAH) has improved dramatically over the past 20 years, there remains no cure and long-term survival is 70% at 3 years. Increasing disease awareness,...
MEDICAL FRONTIERS - European Society of Cardiology (ESC) 2010 Congress
New Focus on Predictability of Antiplatelet Response Generated by P2Y12 Inhibition Trials
Stockholm, Sweden / August 28-September 1, 2010
Stockholm - Individual variability of response to ASA and clopidogrel has shifted attention from the potency of antiplatelet agents to their predictability. Several large clinical trials have demonstrated that newer antiplatelet agents...
MEDICAL FRONTIERS - European Society of Cardiology (ESC) 2010 Congress
Reversible Antiplatelet Agents: Increased Versatility in the Management of Acute Coronary Syndromes
Stockholm, Sweden / August 28-September 1, 2010
Stockholm - In an effort to further reduce the risk of second thrombotic events during and after a myocardial infarction (MI) or other acute coronary syndrome (ACS) events, newer antiplatelet agents are not just being designed to produce a...
PRIORITY PRESS - European Society of Cardiology (ESC) 2010 Congress
Treating Patients at Intermediate Cardiovascular Risk
Stockholm, Sweden / August 28-September 1, 2010
Stockholm - Many patients who can reduce their risk of cardiovascular (CV) events by lipid lowering are being missed entirely by treatment based on LDL-C as an isolated risk factor. In traditional high-risk patients, such as those with a...
FRONTLINE - Geriatric Medicine
Translating Research into Clinical Practice
June 2010
Based on Sessions from the 30th Annual Meeting of the Canadian Geriatrics Society Ottawa, Ontario / April 15-17, 2010 Introduction The Growing Elderly Population: Societal Implications for the 21st Century The Canadian Geriatrics Society...
HEALTH ODYSSEY - Diabetes Management Circle
Blood Glucose Self-Monitoring in Diabetes: Identifying and Dismantling Barriers to Adherence
May 2010
It is clearly important to demonstrate to patients with diabetes that good adherence to self-monitoring of blood glucose (SMBG) favourably affects diabetes control. Among the more recent efforts documenting the relationship between...
MEDI-NEWS - Based on the following article: Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the Bezafibrate Infarction Prevention Trial. Arch Intern Med 2009;169(5):508-14.
Patients Benefiting Most with Fibrate Therapy
May 2010
Studies have consistently shown an inverse correlation between HDL-C levels and cardiovascular (CV) risk in patients with normal or elevated LDL-C levels. As such, guidelines indicate that low HDL-C levels should be regarded as a major risk...
PRIORITY PRESS - 30th Annual Meeting of the International Society of Heart and Lung Transplantation
Vasodilation to Reverse Complications Pre- and Post-heart Transplantation
Chicago, Illinois / April 21-24, 2010
Chicago - Phosphodiesterase type-5 (PDE-5) is abundantly expressed in the lungs. By selectively inhibiting the PDE-5 enzyme, PDE-5 inhibitors promote the accumulation of intracellular cyclic guanosine monophosphate, thereby enhancing nitric...